凯奥拉制药公司获得KIO-104用于眼部炎症疾病的美国专利Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory Diseases

动脉网07-25

Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory DiseasesKiora Pharmaceuticals获得KIO-104在眼部炎症疾病中的美国专利July 25, 20252025年7月25日Kiora Pharmaceuticals has announced the issuance ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2554975495?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-25 15:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2554975495","market":"us","top_or_hot":-1,"title":"凯奥拉制药公司获得KIO-104用于眼部炎症疾病的美国专利Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory Diseases","media":"动脉网","content":"<div>\n<p>Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory DiseasesKiora Pharmaceuticals获得KIO-104在眼部炎症疾病中的美国专利July 25, 20252025年7月25日Kiora Pharmaceuticals has announced the issuance ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515292394ba0551&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>凯奥拉制药公司获得KIO-104用于眼部炎症疾病的美国专利Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n凯奥拉制药公司获得KIO-104用于眼部炎症疾病的美国专利Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-25 15:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515292394ba0551&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory DiseasesKiora Pharmaceuticals获得KIO-104在眼部炎症疾病中的美国专利July 25, 20252025年7月25日Kiora Pharmaceuticals has announced the issuance ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515292394ba0551&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515292394ba0551&s=b","article_id":"2554975495","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515292394ba0551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554975495","pubTimestamp":1753428360,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"这种针对性机制使KIO-104成为炎症性视网膜疾病的一个有前景的候选药物。According to the company, the newly granted patent will extend KIO-104’s market exclusivity through 2043, providing long-term protection for its potential commercial use.据该公司称，新授予的专利将延长KIO-104的市场独占期至2043年，为其潜在的商业用途提供长期保护。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","KPRX":"Kiora Pharmaceuticals","KIO":"KKR Income Opportunities Fund"},"translate_title":"Keora Pharmaceuticals Secures U.S. Patent for KIO-104 for Eye Inflammatory Diseases Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory Diseases","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KIO":1,"KPRX":1},"content_text":"Kiora Pharmaceuticals Secures U.S. Patent for KIO-104 in Ocular Inflammatory DiseasesKiora Pharmaceuticals获得KIO-104在眼部炎症疾病中的美国专利July 25, 20252025年7月25日Kiora Pharmaceuticals has announced the issuance of U.S. Patent No. 12,364,680 for its investigational therapy KIO-104, a small molecule being developed for the treatment of a broad spectrum of ocular inflammatory diseases. The patent enhances Kiora's intellectual property portfolio by protecting the proprietary structure, delivery methods, formulations, dosing schedules, excipients, and therapeutic applications of KIO-104..Kiora Pharmaceuticals 宣布其研发的治疗药物 KIO-104 获得美国专利号 12,364,680，这是一种正在开发用于治疗多种眼部炎症疾病的小分子化合物。该专利通过保护 KIO-104 的专有结构、递送方法、配方、剂量计划、辅料及治疗应用，进一步增强了 Kiora 的知识产权组合。Therapeutic Applications Across Multiple Ocular Conditions多种眼部疾病的治疗应用KIO-104 is being evaluated as a treatment option for several ocular conditions, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and post-refractive surgery complications. As a non-steroidal small molecule, KIO-104 offers an alternative to conventional steroid therapies and systemic anti-inflammatory drugs, which are often associated with significant side effects..KIO-104 正在被评估用于治疗多种眼部疾病，包括眼部炎症、葡萄膜炎、年龄相关性黄斑变性 (AMD) 以及屈光手术后并发症。作为一种非甾体类小分子药物，KIO-104 提供了传统类固醇疗法和全身性抗炎药物的替代方案，而后者常伴随显著的副作用。The molecule exerts its effect by inhibiting dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme essential for the synthesis of DNA and RNA precursors. This targeted mechanism positions KIO-104 as a promising candidate for inflammatory retinal disorders.该分子通过抑制二氢乳清酸脱氢酶（DHODH）发挥作用，这是一种对DNA和RNA前体合成至关重要的线粒体酶。这种针对性机制使KIO-104成为炎症性视网膜疾病的一个有前景的候选药物。“This specific patent is significant in its breadth of therapeutic applications,” said Brian M. Strem, PhD, President and CEO of Kiora Pharmaceuticals. “Securing this patent builds on our IP strategy to protect KIO-104 around its proprietary structure, delivery methods, formulation, and therapeutic applications.”.“这项特定的专利在其广泛的治疗应用方面具有重要意义，” Kiora Pharmaceuticals 总裁兼首席执行官 Brian M. Strem 博士说道，“获得这项专利进一步巩固了我们的知识产权战略，保护 KIO-104 的专有结构、递送方法、配方及治疗应用。”According to the company, the newly granted patent will extend KIO-104’s market exclusivity through 2043, providing long-term protection for its potential commercial use.据该公司称，新授予的专利将延长KIO-104的市场独占期至2043年，为其潜在的商业用途提供长期保护。Phase 2 Clinical Trial Underway第二阶段临床试验正在进行中Kiora is currently conducting the KLARITY study, a multicenter Phase 2 clinical trial designed to evaluate KIO-104 in up to 28 patients with various forms of inflammatory retinal diseases. The study assesses two dose levels, and the results from this initial stage will inform future dose expansion and development strategy..Kiora目前正在开展KLARITY研究，这是一项多中心的2期临床试验，旨在评估KIO-104在多达28名患有各种炎症性视网膜疾病患者中的效果。该研究评估了两种剂量水平，此初步阶段的结果将为未来的剂量扩展和开发策略提供信息。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554975495","isCrawlerRequest":true}